Syngene International Limited, (BSE code: 539268, NSE Id: SYNGENE, ISIN Id: INE398R01022) is one of
Asia’s largest Contract Research Organizations. It provides discovery and developmental services for new
molecular entities across multiple platforms including Small Molecules, Large Molecules, Antibody-Drug
Conjugates and Oligonucleotides. These services are aimed towards bringing novel molecules to the market
by supporting the R&D efforts of organizations across diverse sectors like pharma, biotechnology, nutrition
and animal health. Syngene offers an integrated platform for R&D focussed organizations to optimize their
R&D investments and develop their novel molecules with a distinctive cost advantage
Commenting on this performance, Mr. Peter Bains, Executive Director and Chief Executive Officer - Syngene International Limited said, In our debut results announcement following Syngene’s successful IPO in August, we are very pleased to report a comprehensively strong set of numbers for H1 FY... (more)
Oct 20, 2015 19:42 IST
Syngene International Limited
